Platform
Rooted in Nature, Refined by Innovation
Botanicals:
The Foundation of Discovery
Ajna BioSciences leverages the untapped potential of medicinal plants and fungi, combining time-tested botanics with modern pharmaceutical rigor. Our platform is designed to transform nature’s most promising botanicals into safe, effective, and FDA-approved therapies.
- Time-Tested Species:
We prioritize plant and fungi species with centuries of documented therapeutic use, ensuring a foundation of safety and efficacy recognized across cultures. Our controlled process from farm to lab, utilizing patented genetics, is the first step in producing highly standardized botanical starting material.
- Scientific Validation:
Advanced phytochemical profiling identifies bioactive compounds, enabling us to standardize complex botanical extracts while preserving their natural synergy.
- Sustainability & Ethics:
We partner with global growers committed to regenerative agriculture and fair-trade practices, ensuring ecological and social responsibility from seed to medicine.
An Established Pathway to FDA-Compliant Botanical Drugs
Our Process: From Plant to Prescription
1
Discovery & Sourcing
1. Discovery & Sourcing
- Collaborate with ethnobotanists and traditional healers to identify species with validated historical use.
- Employ AI-driven literature mining to pinpoint understudied botanicals with high therapeutic potential.
2
Standardization & Characterization
STANDARDIZATION & CHARACTERIZATION
- Establish patented genetics and farm to lab process.
- Utilize proprietary CMC (Chemistry Manufacturing, and Controls) protocols to ensure batch-to-batch consistency.
- Map multi-compound interactions using metabolomics and machine learning, meeting FDA requirements for substance characterization.
3
Preclinical & Clinical Development
PRECLINICAL & CLINICAL DEVELOPMENT
-
Design trials that honor botanical complexity while adhering to rigorous regulatory standards.
-
Leverage real-world evidence from traditional use to inform trial endpoints and accelerate development.
- Establish regulatory inteface and feedback loop with expert Key Opinion Leaders (KOL) in each indication.
4
Commercialization & Scalability
Commercialization & Scalability
- Unique optionality for each drug candidate: Exit to or partner with pharmaceutical leaders, pursue vertical integration, and/or license IP for global reach.
- Prime drug candidates with clinical plan for follow-on indications, improving reach, impact, and value of each product.
Competitive Advantages
UNIQUE IP PARADIGM:
Traditional Pharma firms face their greatest profitability threat from generics, but the intricate composition of our botanical mixtures makes them nearly impossible to replicate.
BARRIERS TO ENTRY:
Rigorous CMC and regulatory requirements present substantial hurdles for future competitors seeking to enter the market.
SPEED TO MARKET:
Harnessing cultural and historical usage to identify the most promising opportunities streamlines the drug discovery process and accelerates time to market.